New hope for advanced cancers? pfizer launches early trial of PF-08046033

NCT ID NCT07519655

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may help control the cancer. About 250 people will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma lung neoplasm melanoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS MELANOMA ESOPHAGEAL CANCER NON-SMALL-CELL LUNG

Contacts and locations

Locations

Hospital Oncologico Dr. Isaac Gonzalez-Martinez
RECRUITING

Rio Piedras, 00935, Puerto Rico
Pan American Center for Oncology Trials, LLC
RECRUITING

Rio Piedras, 00935, Puerto Rico
Presbyterian/St Lukes Medical Center
RECRUITING

Denver, Colorado, 80218, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute- Pharmacy
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.